Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine plus bevacizumab in patients with recurrent glioblastoma.
- Resource Type
- Journal
- Source
JOURNAL OF CLINICAL ONCOLOGY ; MAY 20 2017, 35 5p. Supplement: 15- Subject
- Language
- English
- ISSN
- 15277755